Rectal cancer (RC) is a challenging disease to treat that requires chemotherapy, radiation, and surgery to optimize outcomes for individual patients. No accurate model of RC exists to answer fundamental research questions relevant to individual patients. We established a biorepository of 32 patient-derived RC organoid cultures (tumoroids) from patients with primary, metastatic, or recurrent disease. RC tumoroids retained molecular features of the tumors from which they were derived, and their ex vivo responses to clinically relevant chemotherapy and radiation treatment correlate well with responses noted in individual patients' tumors. Upon engraftment into murine rectal mucosa, human RC tumoroids gave rise to invasive rectal cancer followed by metastasis to lung and liver. Importantly, engrafted tumors closely reflected the heterogenous sensitivity to chemotherapy observed clinically. Thus, the biology and drug sensitivity of RC clinical isolates can be efficiently interrogated using an organoid-based, in vitro platform coupled with endoluminal propagation in animals.
Introduction
Colon and rectal cancers are responsible for 50,000 deaths per year in the United States 1-3 . Rectal cancer (RC)
is particularly challenging, as treatment after diagnosis is more complex compared to colon cancer 4 due to tumor location in the pelvis and proximity to critical genitourinary organs. Rectal cancer invading the perirectal tissues or lymph nodes are treated with tri-modal therapy which consists of neoadjuvant chemoradiation (CRT), surgical resection, and chemotherapy 4 . Some RC patients respond completely to CRT alone and can avoid surgery entirely 5, 6 , but others respond poorly and require radical surgery 7 . Prospective identification of patients who would achieve a complete response 7, 8 after neoadjuvant therapy alone would enable more tailored individual treatment regimens 9, 10 and thereby minimize potential harm from overtreatment. The heterogeneity in clinical response and the morbidity associated with radical surgery highlights the need for more sophisticated modeling to predict response to standard therapies.
Few cell lines have been derived from RCs [11] [12] [13] [14] . Despite the fact that RC is treated differently from colon cancer by using tri-modal therapy in a neoadjuvant context, the preclinical development of treatments for rectal cancer has historically relied on colon cancer cell lines 15 , highlighting the need to develop RC-specific models.
Furthermore, efforts to derive organoid "biobanks" have focused primarily on colon cancer specimens 16 , with a biorepository of rectal cancer tissue or organoids remaining an unmet need for the field.
An additional need for rectal cancer research is an anatomically accurate in vivo model using patient-derived RC organoids. The rectum has unique venous drainage via the iliac vessels that gives rise predominantly to lung metastases 17 (69%), and less frequently liver metastases (20%), which are more commonly seen in colon cancers. Given recent success transplanting mouse colon cancer cells into the colon lumen by our group 18 and others 19 , we set out to derive RC organoids (hereafter "tumoroids") from resected or biopsied RCs and use them to establish ex vivo and in vivo RC model. We investigated the ability of such tumoroids to model the molecular and histologic features of human rectal cancers, as well as tumor initiation, invasion and metastasis. We also investigate whether our ex vivo and in vivo platforms could be used to correlate with treatment response in individual patients within a time frame that could potentially inform clinical treatment decisions.
Fig. 1 Results

Human RC tumoroid derivation and characterization
With the goal of generating RC models that would reflect the biology of an individual patient's tumor, we adapted existing strategies for 3D ex vivo tumor culture 20, 21 to generate RC tumoroids from pre-and posttreatment patient samples. Basic characteristics of all patients from whom we attempted tumoroid derivation are shown in Extended Data Figure 1 . Overall, we established 32 RC tumoroids from 25 individual patients with an overall success rate of 76% (32/42) . In addition to these RC tumoroids, we also generated 19 normal rectal organoids from normal adjacent tissue (see Supplementary Table 1) . Of the ten failed tumoroid attempts, three were maintained for 6 weeks before senescing. As expected from previous work in colon cancer, RC tumoroids could be cultured in the absence of key growth factors 16 (e.g., R-spondin, Wnt-3a, Noggin), whereas normal rectal organoids remained growth factor dependent 21 .
Since endoscopic biopsies are routinely performed in the outpatient setting in the treatment of patients with rectal cancer, we asked whether we could derive RC tumoroids from minute amounts of material obtained in the clinic. Of note, 17 of the RC tumoroids were established using tissue obtained with biopsy forceps routinely used in clinical care (Fig. 1a) . These data suggest it is possible to use serial biopsies obtained as part of standard care in the pre-treatment or post-therapy settings to generate tumoroid models to assess patient-specific mediators of response and resistance.
Despite concern that tumor stem cells exposed to prior systemic chemotherapy or radiation would not likely yield viable tumoroids 16 , we were able to generate RC tumoroids and normal adjacent rectal organoids from patients who had undergone prior chemotherapy and/or radiotherapy, as well as those who had no prior therapeutic intervention before surgical resection. Of the 32 tumoroids, 9 were derived from treatment-naïve patients, 17 from patients undergoing first or second line therapy (Supplementary Table 1 ). The remaining 6
were derived from patients with sites of disease recurrence: 4 perineal local recurrences and 2 metastases (a paired splenic metastasis and a peritoneal metastasis). Tumoroids were derived from all sites of the rectum (i.e., distal, mid and upper), from RAS mutant (64%) and wild type tumors, and from patients with metastatic disease (48%) and non-metastatic disease (Extended Data Fig. 1 ). In summary, we sampled a diverse set of RC patients with different stages of disease, on or off therapy, RAS mutant and wild type status, and did not find any clinical variables that predicted success or failure of organoid establishment.
Histopathologic and molecular characteristics are preserved in rectal cancer tumoroids
As with cancer organoids derived from other tissues, RC tumoroids retained histopathologic features of the primary tumors, such as preservation of the glandular structure and lumen (Fig. 1a, Extended Data Fig. 2 ).
Further, RC tumoroids retained Alcian blue-positive and MUC-2-positive goblet cells, CK20 and CDX2-positive enterocytes, and robust expression of E-cadherin (epithelial marker), mirroring the tumors from which they were derived (Fig. 1b, Extended Data Fig. 3 ). The tumoroids demonstrate variable CDX2 staining, as seen in the primary tumor. These data indicate that features found in the primary tumor are retained in the tumoroid from which it was derived and reflect individual patient tumors.
To determine whether the RC tumoroids also reflect the mutational fingerprint in the corresponding primary tumors-as well as the larger landscape of molecular alterations in RC-we performed massively parallel sequencing using the custom, FDA-cleared tumor profiling panel MSK Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) 22 . We sequenced genomic DNA isolated from 15 were also present as clonal in tumoroid samples. We then compared these tumoroids to a clinical cohort of 291 rectal cancers resected at Memorial Hospital that had been sequenced by MSK-IMPACT. The top mutations in the 291 rectal cancer patients were also noted in the RC tumoroids, with the most common alterations in the genes APC, TP53, KRAS, and FBXW7 (Fig. 1c) .
Fig. 2
RC tumoroids reveal a diversity of responses to chemotherapy that correlate with clinical response
We next examined our RC tumoroids as a platform for preclinical studies using the established RC tri-modal treatment approaches. 5-fluorouracil (5-FU) is the backbone of RC chemotherapy as part of systemic therapy or in combination with radiation 24, 25 . Treatment of six different RC tumoroids with 5-FU yielded significant differences in cell death ( Fig. 2a ; Kruskal-Wallis test for nonparametric data, P < 0.02) and heterogeneous IC50 values (range: 34-800 μM, Fig. 2b , right axis). Within the therapeutic dosage range noted clinically 26 (19) (20) (21) (22) (23) μM, shown as grey box in Figure 2a) , we observed significant differences in cell death among the tumoroids .
Thus, the RC tumoroids are heterogeneous in their response to physiologic 5-FU doses, suggesting that they could be used as a tool to predict patient response to 5-FU treatment.
We then asked whether ex vivo 5-FU sensitivity correlated with a parameter of clinical utility in the corresponding patients as assessed by carcinoembryonic antigen (CEA), which is a marker of active disease or recurrent disease 27, 28 . The change in CEA levels from baseline for the RC-MSK-003 and RC-MSK-008 patients with higher IC50 values was larger (+37% and +48%) than it was for the RC-MSK-001PR and RC-MSK-001 (+2.9% and -29%) and the RC-MSK-002 and RC-MSK-004 patients (-67% and -17%) ( and RC-MSK-003 (D0 = 11.0) were resistant to radiation ex vivo (Fig. 2c) . Ex vivo RT sensitivity of the RC-MSK-001 and RC-MSK-003 tumoroids correlated with clinical RT sensitivity of the tumors from which they were derived as assessed by changes in luminal circumference of the tumor by endoscopy before and after radiation ( Fig. 2d : RC-MSK-001, 60% of circumference to 30%; RC-MSK-003, 90% of circumference to 80%). The patient from which RC-MSK-002 was derived was not treated with neoadjuvant radiation. Taken
together, these data demonstrate that RC tumoroids display varying sensitivity to ionizing radiation, indicating that this platform could be used to evaluate patient response before initiating this treatment modality and potentially sparing resistant patients the toxic side effects of radiation therapy 29 .
Proof-of-principle targeted therapy studies in RC tumoroids
In colorectal cancers, the presence of KRAS mutation predicts resistance to EGFR-targeted therapy; therefore, we asked whether RC tumoroids would recapitulate KRAS mutation-mediated resistance to the anti-EGFR monoclonal antibody cetuximab 30 . Consistent with clinical data, KRAS mutant tumoroids were resistant to cetuximab, whereas KRAS wild type tumoroids were sensitive (Extended Data Fig. 6 ). These data provide preliminary evidence that a cell-autonomous response in RC tumoroids reflects a clinically important response to a targeted therapy that could readily be assayed ex vivo to functionally determine individual patient responses.
Fig. 3
Establishing an endoluminal model using human rectal cancers
We next sought to establish an orthotopic, patient-derived xenograft model of RC that could reflect the initiation, invasion, and metastatic potential of tumors that develop in the unique anatomy of the rectum. Fig. 3a shows the methodology 18 We then interrogated our model for to the development of invasive cancer and metastatic disease. At 22 weeks and 30 weeks post-transplantation, we noted progression to invasive adenocarcinoma that parallels the features of stage I or II human rectal adenocarcinomas ( Fig. 3c and Extended Data Fig. 9 ). Importantly, we noted evidence of metastases in the lung (Fig. 3d) and liver (Extended Data Fig. 10a ) that demonstrated features of poorly differentiated carcinomas infiltrating normal parenchyma, as confirmed by independent pathological review. Notably, the metastases derived from the endoluminal rectal tumors corresponded to sites of metastases seen in the individual patients from which the tumoroids were derived, namely lung metastases in the case of RC-MSK-001 and liver for RC-MSK-002 ( Fig. 3d lower panel, Extended Data Fig. 10b , respectively). The metastases were further confirmed with human-specific PCR analyses (Extended Data Fig. 10c ). These data indicate the feasibility of a patient-derived RC endoluminal model and its patterns of clinically relevant metastasis.
Fig. 4
The endoluminal model as a platform to investigate chemosensitivity
We hypothesized that we could mimic chemotherapy response in our in vivo RC model as a parallel, pre-clinical assay to our ex vivo work. To establish safe use of 5-FU in vivo, we first conducted experiments in a subcutaneous injection model and treated the mice systemically with 50 mg/kg/week of intraperitoneal injection 5-FU. The tumoroids successfully engrafted, the mice tolerated treatment well, and we noted a level of response in two separate tumoroid lines (Extended Data Fig. 11 ).
After showing safe use of 5-FU in vivo, we then tested whether we could demonstrate chemosensitivity in our endoluminal RC model. We implanted mice with tumoroids from two lines: RC-MSK-008, which was 5-FU-insensitive both clinically and ex vivo, and RC-MSK-004, which was 5-FU-sensitive in both circumstances ( 
Discussion
We have established a biorepository of RC models representing the spectrum of genetic diversity and treatment response seen in RC. This unique resource represents a significant expansion of the reagents for the study of RC and will enable mechanistic and translational studies to be performed on bona fide RCs, rather than surrogate colon cancer cell lines. Importantly, RC tumoroids can be routinely and successfully established from small amounts of starting material using a 2.8 mm biopsy forceps, demonstrating that only a small amount of tissue is required to derive a viable tumoroid line and that samples can be obtained in the outpatient clinic. We have demonstrated that RC tumoroids from patients successfully engraft into the rectal mucosa of mice and that these orthotopic, endoluminal rectal xenograft mouse models recapitulate patient-specific treatment response in vivo.
Notably, we contribute new methodology and modeling with regard to ex vivo radiation response and patientspecific in vivo chemotherapy response in our endoluminal model. To our knowledge, the correlation demonstrated here with radiation in RC tumoroids is the first demonstration of this ex vivo technology as it relates to clinical response in a disease where radiation is standard of care. Further, our data suggest that the ex vivo and in vivo models we have derived are a representative analog of individual RC patient response, complementing what has been recently described for other metastatic adenocarcinomas 31 .
Despite concerns that organoid technology would be unsuccessful with heavily pre-treated tumor specimens 16 , our findings are especially important as our work shows that this is possible with a success rate of ~75%. We have demonstrated that the basic histopathology and enterocyte differentiation markers are conserved between RC tumoroids and primary tumors. The mutational profiles between tumor and derived tumoroid were conserved and we noted similarity between our derived RC tumoroids and an independent MSK-Rectal Cancer Cohort ( Fig. 1) .
Recapitulation of patient-specific and clinically relevant responses to chemotherapy, irradiation, and targeted therapy may open doors to determine new and more precise treatments for RC patients. Furthermore, the derivation of RC tumoroids and normal rectal organoids from biopsies is critically important, as this means models can be derived at diagnosis or at the time of recurrence from minute amounts of biopsy material. Ex vivo and in vivo sensitivity to standard and experimental therapeutics (e.g. trials), as well as irradiation, could be fully assayed in 6-12 weeks after establishment (Figs. 2 and 3) . If the individual patient fails standard treatment or experiences progressive disease, these assays may provide rationale to attempt new therapies found to be effective both ex vivo and in vivo using the patient's own tumor tissues as the embedded informant. These data could be gathered within the period it takes a modern-day RC patient to undergo total neoadjuvant therapy (6 months) 32 . Future work will leverage our model to prospectively evaluate the concordance between patient and tumoroid response to standard therapeutics, including both chemotherapy and radiation.
Additional novelty of this work lies in the establishment of the endoluminal RC model that recapitulates clinical response to therapy. This model builds on our recent murine model of transplantation 18 , but is also the first demonstration that treated and untreated human RC tumors can engraft within the mouse rectum and recapitulate the process of primary disease formation, subsequent invasion, and eventual metastasis. Notably, we observed the development of metastases that may signal tropism of the human RCs from which the tumoroids were derived. While these findings are intriguing, they require prospective validation in a larger cohort. Overall, these data indicate that we have established a working RC platform to better elucidate RC pathogenesis and address questions regarding chemosensitivity and radiation resistance.
In summary, our work addresses an unmet need by establishing a rectal cancer-specific ex vivo and in vivo biorepository that markedly increases the ability to study rectal cancer. Our model molecularly resembles RC and establishes a relevant framework in which to study the disease. This methodology demonstrates options for eventual drug screening 33 in a pre-clinical setting and reflects the clinical outcomes of the patients from which they were derived. Our study demonstrates determination of basic response parameters within weeks of derivation and can serve as a robust tool for therapeutic response modeling whereby we can study fundamental research questions relevant to individual RC patients.
Methods:
Data availability statement
The data that support the findings of this study are available from the corresponding authors upon reasonable request. The data for the RC tumoroids on the cBioPortal will be made publicly available on publication.
Study Design
We developed a 3D organoid system to culture patient-derived rectal cancer (RC) specimens from treated and untreated patients and dissociated 3D tumoroid and normal adjacent rectal cells (organoids) for long-term use.
We developed an in vivo orthotopic, xenograft endoluminal model of rectal cancer with the tumoroids and tested initiation, invasion, tumor growth and chemoresistance in this endorectal endoluminal model. After the Matrigel balls were polymerized, 500 μL of culture medium was added.
Statement of compliance with internal review boards
To freeze organoids or tumoroids, Matrigel was dissolved with cell recovery solution and then the cell clusters were pelleted. The pellets were resuspended in ice-cold Recovery Cell Culture Freezing Medium (Gibco, Waltham, MA, USA). The pellets also could be dissociated with TrypLE express before Freezing Medium was added. The suspension was frozen down slowly at -80 °C at least overnight followed by storage in liquid nitrogen. The frozen cells were recoverable with standard cell recovery protocol 21 , could be embedded in Matrigel, and culture started as described above. Tumoroids were judged to be successful if they met the following criteria: maintenance in culture for > 4 weeks, viability after five serial passages, and ability to resume growth following multiple freeze/thaw cycles.
Endoluminal tumor injections
Adapting the dextran sulfate sodium endoluminal protocol 18 
5-FU treatment of mice with endoluminally implanted tumors
RC-MSK-008 tumoroids were injected into the rectum (see Fig. 4 ) of 15 female (sex matched to tumoroid) mice 6-8 weeks of age. Mice were checked for the progression of tumor using endoscopy at 3-4 week intervals.
Then, the 14 mice that were successfully engrafted as evidenced by tumor formation noted on endoscopy were randomized by the envelope method into two groups and intraperitoneally injected with either 5-FU (5 mg/mL in PBS, 50 mg/kg/week), or PBS as control for the duration of the experiment. After 7 weeks of treatment, the tumors were assessed using endoscopy. All of the mice were sacrificed, and rectum, colon, cecum, liver, lung, and brain were isolated and fixed in formalin overnight. Separately, RC-MSK-002 tumoroids were injected into 15 male (sex matched to tumoroid) mice 6-8 weeks of age (see Fig. 4 ). 3 mice did not survive DSS treatment due to severe colitis, and of the remaining 12 mice, 11 successfully engrafted and were treated similarly as with the RC-MSK-008 experiment above.
To quantify tumor size, two independent observers reviewed all endoscopy videos and took screenshots when the endoscope had the tumor in full view. The field of view and tumor were circled and the areas were measured using ImageJ software (NIH). When there were multiple tumors, the sum of the total tumor area was taken. These data are presented as (Area of tumor)/(Area of the field of view) ×100%.
Ectopic tumor injections
The tumoroids were released from Matrigel by using cell recovery solution and then resuspended in 50% icecold PBS and Matrigel (product #356237) solution to a concentration of 1×10 6 viable cells per mL. Mice under anesthesia were subcutaneously inoculated with 1×10 5 viable cells in the both hind flanks (100 μL/site). For the RC-MSK-001 experiment, tumors were grown for 6 weeks and for the RC-MSK-002 experiment, tumors were grown for 7 weeks. After this time, the mice were randomized into two groups and intraperitoneally injected with either 5-FU (50 mg/kg), or PBS as control, twice per week for the duration of the experiment. Tumor sizes were measured weekly using a handheld imaging device (Peira TM900).
Development of the GFP-labeled tumoroid and endoscopic viewing of GFP
The RC-MSK-001-eGFP/luc tumoroids used for bioluminescent tracking were developed by lentivirally introducing GFP and firefly luciferase. Lentiviral particles were generated by transfecting HEK293T cells with the Ubc-eGFP-Luc, psPAX2, and VSV-G 35 constructs. 7.25 × 10 6 HEK293T cells were seeded into a 10 cm dish. 7.7 µg of the lentiviral construct, 5.8 µg of psPAX2, and 3.9 µg of VSV-G were transfected using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen), grown overnight, and then the medium was replaced with standard DMEM supplemented with 10% FBS, GlutaMAX, and PenStrep. Two days after transfection, the virus media was concentrated using PEG-it Virus Precipitation Solution (SBI System Biosciences), and then the lentiviral particles resuspended in 300 µL PBS. For RC-MSK-001 tumoroid infection, tumoroids from three 50µL Matrigel discs per viral construct were dissociated and resuspended in 10 µL of infection medium (tumoroid culture medium plus 8 µg/mL Polybrene [SigmaAldrich], and 10 µM Y27632 [SigmaAldrich]). The tumoroid cluster suspension and viral suspension were combined in a 48-well culture plate, centrifuged at 600×g at room temperature for 60 minutes, and then incubated for 6 hrs at 37 °C and 5% CO2. The contents of each well were homogenized, transferred to a 1.5 mL tube, and centrifuged at 400×g. The supernatant was discarded, the pellet resuspended in 150 µL Matrigel, and the suspension divided into three wells of a 24-well suspension plate. After Matrigel polymerization, 500 µL of culture medium with 10 µM Y27632 was added. Two days after infection, the medium was replaced with tumoroid culture medium.
The infected cells were selected for by addition of puromycin (2µg/mL) for 6 days, and then further enriched by fluorescence-activated cell sorting for GFP-positive cells.
Preparation of tumoroids and tissues for immunohistochemistry and immunofluorescence
After removal of culture medium, the Matrigel disc was washed with PBS, and then fixed with 4% paraformaldehyde for 30 min at room temperature. Then paraformaldehyde was removed, and the fixed sample was stained with eosin and transferred carefully to an embedded cassette. Paraffin embedding and sectioning were processed with standard protocols. Tissues were fixed in formalin and embedded in paraffin. 5 µm sections were used for analysis.
Immunohistochemistry and immunofluorescence
Hematoxylin and eosin stains were performed on all specimens for initial histopathological evaluation. Immunoglobulins specific for each species were used as negative control.
Imaging
Slides were scanned using the Pannoramic Flash slide scanner (3DHISTECH) using a 20x 0.8 NA objective (Carl Zeiss). Images were examined and representative areas exported using CaseViewer 2.2 (3DHISTECH).
Alu quantitative PCR
To quantitatively characterize the metastases noted within the mouse lungs and livers as human cells originating from the rectal xenografts, quantitative polymerase chain reaction (q-PCR) was performed with primers specific for human Alu repeats 37 and mouse short interspersed nuclear elements (SINE) 38 
DNA isolation
Tumoroids and normal organoids were released from Matrigel by using cell recovery solution. DNA was extracted using DNeasy Blood and Tissue kit according to the manufacturer's procedure (Qiagen, Germantown, MD, USA).
Genomic Analysis
DNA derived from the tumor biopsies and the cultured tumoroids was subjected to exon capture sequencing using the MSK Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) platform as previously described 39 . Matched germline DNA samples, extracted from blood and cultured normal organoids, were also sequenced to identify somatic versus germline nucleotide variants. Somatic variants were called using MuTect (v1.1.4) for single nucleotide variants and Somatic Indel Detector (GATK 2.3-9) for indels. Somatic variants were annotated by Annovar for cDNA and amino acid changes and for their presence in dbSNP (v137), the COSMIC database (v68), and 1,000 Genomes minor allele frequencies. Variants were also annotated for their presence and predicted oncogenic status in OncoKB 40 . Each locus where a variant was called was genotyped in matched timepoint samples from the same patient. If a variant was called in one sample and was present in another sample from the same patient in at least 3 reads and at least 1% of reads, it was marked as 'detectable' in the other sample. We considered the most frequently mutated genes in the tumoroids and compared their mutation frequency within the tumoroid cohort with the mutation frequency in a set of 291 prospectively analyzed rectal adenocarcinoma samples from MSK. These data can be viewed on the cBioPortal for Cancer Genomics 41, 42 . In addition, we used the FACETS algorithm to determine allele specific copy number and cancer cell fraction of each mutation in tumoroids and their respective tumors 43 . Mutations with higher or equal to 85% cancer cell fraction were categorized as clonal. Others were categorized as subclonal.
Drug treatments
Tumoroids were resuspended in Matrigel and embedded in suspension in a 24-well plate (2-5×10 4 cells/50 μL Matrigel/well) or 48-well plate (2-3 ×10 3 cells/20 μL Matrigel/well). The cells were allowed to recover for 2 to 3 days. Medium was replaced with fresh culture medium with varying concentrations of the drugs as follows.
For cetuximab treatments, KRAS mutant and KRAS wild type tumoroids were cultured with cetuximab at 20, 10, 5 and 2.5 μg/mL for 72-hours. For 5-FU treatments, tumoroids were cultured with 5-FU at 500, 100, 50, 10, 5, 1, and 0.5 μM for 6 days, replenishing 5-FU medium on day 3. At the end of treatment in both experiments, the number of viable cells was determined by MTS assay or CellTiter-Glo assay (Promega, Madison, WI, USA)
following the kit protocol. IC50 values were determined using the Variable Slope Model to calculate a fourparameter dose-response curve using GraphPad Prism 7 (La Jolla, CA, USA).
CEA assessments
CEA was measured clinically (ng/mL) over the course of treatment from baseline for the patients from which the 6 individual RC tumoroids were derived as noted in Figure 2b . The CEA values from baseline and posttreatment were retrieved from the medical record for each patient from which the tumoroids were derived in Figure 2 . Percent change from baseline was reported as described in the results.
Irradiation experiments
The tumoroid samples were given to our collaborators (MA, PBP) without supplying any information on the Tumoroids were passaged one day prior to the experiment and plated at a density of 100-150 organoids/well in at least 3 wells for each dose. Tumoroids were exposed to single fraction radiation (range 0-20Gy). Six days after irradiation, surviving organoids were manually counted under a brightfield microscope classic doseresponse curves were generated. The survival fraction was calculated as the number of surviving tumoroids/number of tumoroids in the un-irradiated sample. Radiation dose survival curves were fitted to the Single Hit Multi Target (SHMT) model 44 using GraphPad Prism 6. This model allows calculation of D0 (the dose required to reduce the fraction of surviving tumoroids to 37% of its previous value) and Dq (a threshold dose below which there is no effect) as described 44 .
Statistics:
Statistical analyses reported in Figure 2a were 
